# FLT3-ITD Targeted Therapy in Fit AML Patients

> **NCT07425808** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 230 (estimated)

## Conditions studied

- AML (Acute Myeloid Leukemia)

## Interventions

- **DRUG:** Gilteritinib
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine (AZA)
- **DRUG:** Local standard of care (SOC)

## Key facts

- **NCT ID:** NCT07425808
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2028-10-01
- **Final completion:** 2032-02-01
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07425808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07425808, "FLT3-ITD Targeted Therapy in Fit AML Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07425808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*